News – Page 368 – Endpoints News

An eye, 15 seconds and striking animation: How Horizon's thyroid eye disease campaign hit home with patients

3 years ago

Novartis CEO takes pay cut as AbbVie's Rick Gonzalez nabs nearly 10% raise

3 years ago

FDA inspection uncovers cherry-colored antibiotic residue on equipment at Teva's New Jersey site

3 years ago

FDA says no adcomm planned for Biogen, Sage's depression drug

3 years ago

BioMarin seeks label expansion for achondroplasia drug; FDA lifts Inhibikase full clinical hold

3 years ago

Mesoblast’s aGVHD cell therapy will get another shot at the FDA

3 years ago

Ex-NIH, Sanofi leaders nab Merck support for their biotech’s Epstein-Barr vaccine

3 years ago

Francis Collins readies a Biden push to eliminate hepatitis C nationwide

3 years ago

Oncopeptides exec is arrested in Sweden for allegedly passing insider information

3 years ago

Biotech pain continues as Versant, MPM gene therapy startup calls it quits

3 years ago

With PhII fail, Redx Pharma scraps monotherapy biliary cancer development for lead program

3 years ago

Makena saga nears an end as Covis requests to pull controversial preterm birth drug

3 years ago

Bristol Myers axes German launch of new cancer drug, citing pricing hurdles

3 years ago

Where are all the generic inhalers for asthma and COPD? Researchers call for patent and FDA reforms

3 years ago

AbbVie braces for 'greater erosion' of Humira franchise in second half of this year

3 years ago

Gilead plans to invest $47M+ to boost its capacity in southern Ireland

3 years ago

Moderna selects Oxfordshire for new research and manufacturing site

3 years ago

South by Southwest 2023 health preview: The pharmas, the panels and the inspiration land in Austin this week

3 years ago

MarketingRx roundup: Genentech doubles down on anti-racism; Eli Lilly rolls first social video on $35 or less insulin

3 years ago

F-star's sale to Chinese buyer cleared by CFIUS following months of holdup

3 years ago

Despite mid-stage plaque psoriasis win, J&J appears undecided on PhIII for partner's IL-23 drug

3 years ago

Lenz Therapeutics eyes better vision than AbbVie, Orasis with $80M+ for three PhIII trials

3 years ago

BridgeBio to raise $150M; FDA accepts Ionis' antisense drug NDA

3 years ago

Alex Denner's firm takes over Amarin, ousts non-Sarissa board members

3 years ago

First page Previous page 365 366 367368369 370 371 Next page Last page